RenovoRx (RNXT) Return on Assets (2021 - 2026)

RenovoRx (RNXT) posted Return on Assets of 0.01% for Q1 2026, up 12.16% sequentially from 0.02% in Q4 2025, and up 1.0% YoY from 0.01% in Q1 2025.

RenovoRx (RNXT) Return on Assets (2021 - 2026) Analysis & Trends

RenovoRx has reported Return on Assets for 6 years, with the latest figure at 0.01% in Q1 2026.

Quarterly Return on Assets rose 1.0% year-over-year to 0.01% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.01% (up 1.0% YoY) and the FY2025 annual result came in at 0.04%, up 2.0% from the prior year.
Return on Assets climbed to 0.01% in Q1 2026 per RNXT's latest filing, from 0.02% in the prior quarter.
Over five years, Return on Assets peaked at 0.01% in Q1 2022 and troughed at 0.06% in Q4 2023.
A 5-year average of 0.02% and a median of 0.02% in 2025 frame the typical range for Return on Assets.
The sharpest annual moves came in 2023 and 2024: Return on Assets decreased 5 bps in 2023, then grew 3 bps in 2024.
Over 5 years, Return on Assets stood at 0.02% in 2022, then plunged by 281 bps to 0.06% in 2023, then soared by 50 bps to 0.03% in 2024, then surged by 52 bps to 0.02% in 2025, then grew by 12 bps to 0.01% in 2026.
According to Business Quant data, Return on Assets over the past three periods registered 0.01%, 0.02%, and 0.02% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROA (Qtr)
1	Vertex Pharmaceuticals	140.23 Bn	132.38 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	86.97 Bn	78.97 Bn	3.93 Bn	0.00%
3	Argenx Se	65.29 Bn	60.11 Bn	1.37 Bn	-
4	Moderna	59.88 Bn	54.74 Bn	52.00 Mn	0.00%
5	BeOne Medicines	42.20 Bn	37.11 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.62 Bn	28.31 Bn	992.69 Mn	0.00%
7	BioNTech SE	28.69 Bn	10.30 Bn	668.28 Mn	0.00%
8	Insmed	27.51 Bn	26.35 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.16 Bn	26.33 Bn	-	0.00%
10	RenovoRx	61.72 Mn	61.72 Mn	766,000.00	-0.01%

Download Data